Printer Friendly

DIAGNOSTEK ANNOUNCES PRICING OF COMMON SHARE OFFERING

 DIAGNOSTEK ANNOUNCES PRICING OF COMMON SHARE OFFERING
 ALBUQUERQUE, N.M., Dec. 3 /PRNewswire/ -- Diagnostek, Inc.


(NYSE: DXK), today announced it has priced its pending 3.9 million common share offering at $22-7/8 per share. Approxiately 3.5 million of the common shares were sold by the company while the balance of the shares were sold by non-affiliated selling shareholders. The company and a selling shareholder have also guaranteed underwriters an overallotment option with respect to an additional 585,000 shares. The offering was mangaged by Bear, Stearns & Co. Inc., Dillon, Read & Co., Inc., Wertheim Schroder & Co., Incorporated, and Dean Witter Reynolds, Inc.
 The company will use the approximately $76 million of net proceeds to fund the future growth of the company. Diagnostek is a leading provider of comprehensive pharmacy services designed to contain the cost of dispensing pharmaceuticals. The company dispenses prescription drugs by mail to beneficiaries of health benefit plans and provides contract pharmacy management services to hospitals, managed care providers and other institutions.
 -0- 12/3/91
 /CONTACT: Vincent Villanueva or Dennis Evans of Diagnostek, 505-345-8080/
 (DXK) CO: Diagnostek, Inc. ST: New Mexico IN: MTC SU:


GK -- NY013 -- 8618 12/03/91 09:04 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:198
Previous Article:NEW ANTI-VIRAL COMPOUND REPORTED BY LIDAK PHARMACEUTICALS
Next Article:KAWASAKI, CYCLE SPORTS OF SALEM TO AWARD NESTUCCA FIRE-WATER RESCUE DEPT. WITH OUTSTANDING PUBLIC SERVICE AWARD, WEDNESDAY, DEC. 4
Topics:


Related Articles
DIAGNOSTEK ANNOUNCES SECOND QUARTER RESULTS
DIAGNOSTEK ANNOUNCES PRICING OF COMMON SHARE OFFERING
AMEX BEGINS TRADING OPTIONS ON ARROW ELECTRONICS; DIAGNOSTEK; ENZON; LIPOSOME TECHNOLOGY; AND T CELL SCIENCES
DIAGNOSTEK ANNOUNCES FINANCIAL RESULTS
DIAGNOSTEK NAMES WILLIAM A. BARRON CHIEF FINANCIAL OFFICER
DIAGNOSTEK, INC. REPORTS FISCAL 1993 RESULTS
DIAGNOSTEK FIRST QUARTER FISCAL 1994 RESULTS
DIAGNOSTEK, INC. SIGNS PRESCRIPTION DRUG AGREEMENT WITH AFLAC
DIAGNOSTEK SECOND QUARTER FISCAL 1994 RESULTS
DIAGNOSTEK ANNOUNCES NEW PRESCRIPTION CREDIT CARD PRODUCT SPONSORED WITH THE NATIONAL RURAL ELECTRIC COOPERATIVE ASSOCIATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters